Kiniksa Pharmaceuticals Reports Record Revenue Growth Amid New Marketing Campaign
Kiniksa Pharmaceuticals (NASDAQ: KNSA) reported a record $214.27 million in Q1 revenue, reflecting a 56% year-over-year increase driven by strong ARCALYST sales and the launch of a direct-to-consumer TV campaign. The company raised its full-year revenue guidance to between $930 million and $945 million.
Topics: earnings report guidance update pharmaceuticals revenue growth